Cetera Advisor Networks LLC Novavax Inc Transaction History

Cetera Advisor Networks LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$5.76 - $12.48 $27,504 - $59,592	4,775 Added 29.02%	21,227 $147,000
Q4 2022 Feb 14, 2023	SELL	$8.86 - $25.04 $221 - $626	-25 Reduced 0.15%	16,452 $169,000
Q3 2022 Nov 10, 2022	BUY	$18.2 - $76.12 $31,194 - $130,469	1,714 Added 11.61%	16,477 $300,000
Q2 2022 Aug 11, 2022	BUY	$36.28 - $75.29 $247,647 - $513,929	6,826 Added 86.0%	14,763 $759,000
Q1 2022 May 12, 2022	BUY	$69.73 - $142.9 $172,930 - $354,392	2,480 Added 45.45%	7,937 $585,000
Q4 2021 Feb 14, 2022	BUY	$134.56 - $217.97 $290,784 - $471,033	2,161 Added 65.56%	5,457 $781,000
Q3 2021 Nov 16, 2021	BUY	$177.8 - $270.58 $189,890 - $288,979	1,068 Added 47.94%	3,296 $683,000
Q2 2021 Aug 13, 2021	BUY	$121.0 - $257.67 $269,588 - $574,088	2,228 New	2,228 $473,000
Q3 2020 Nov 13, 2020	SELL	$79.44 - $178.51 $23,832 - $53,553	-300 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$13.86 - $83.61 $4,158 - $25,083	300 New	300 $25,000

284

83.2M

5.43M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $1.01B
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Cetera Advisor Networks LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisor Networks LLC with notifications on news.